The Association of Fenofibrate with Kidney Tubular Injury in a Subgroup of Participants in the ACCORD Trial.
作者信息
Chauhan Kinsuk, Nadkarni Girish N, Debnath Neha, Chan Lili, Saha Aparna, Garg Amit X, Parikh Chirag R, Coca Steven G
机构信息
Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
Institute for Clinical Evaluative Sciences, Toronto, Canada.
出版信息
Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1521-1523. doi: 10.2215/CJN.00370119. Epub 2019 Aug 13.
Abstract
摘要
相似文献
1
The Association of Fenofibrate with Kidney Tubular Injury in a Subgroup of Participants in the ACCORD Trial.
Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1521-1523. doi: 10.2215/CJN.00370119. Epub 2019 Aug 13.
2
Fenofibrate: altered renal function.
Prescrire Int. 2011 Jun;20(117):154-5.
3
Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience.
Diabetologia. 2012 Jun;55(6):1641-50. doi: 10.1007/s00125-012-2524-2. Epub 2012 Mar 27.
4
[Perspectives of the use of fenofibrate in patients with type 2 diabetes mellitus: what is new after the ACCORD Study?].
Kardiologiia. 2011;51(9):68-74.
5
Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study.
Diabetes Care. 2012 Feb;35(2):218-25. doi: 10.2337/dc11-1109. Epub 2011 Dec 30.
6
The relationship of neutrophil elastase and proteinase 3 with risk factors, and chronic complications in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) sub-study.
Diab Vasc Dis Res. 2021 Jul-Aug;18(4):14791641211032547. doi: 10.1177/14791641211032547.
7
Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.
Am J Cardiovasc Drugs. 2011 Aug 1;11(4):227-47. doi: 10.2165/11207690-000000000-00000.
8
The FIELD study.
Lancet. 2006 Apr 8;367(9517):1141-2; author reply 1142-3. doi: 10.1016/S0140-6736(06)68500-0.
9
Fenofibrate-induced rhabdomyolysis in two dialysis patients with hypothyroidism.
Nephrol Dial Transplant. 1999 Apr;14(4):1047-8. doi: 10.1093/ndt/14.4.1047.
10
The FIELD study.
Lancet. 2006 Apr 8;367(9517):1141; author reply 1142-3. doi: 10.1016/S0140-6736(06)68499-7.
引用本文的文献
1
Renal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions.
Drugs. 2025 Mar 19. doi: 10.1007/s40265-025-02158-0.
2
Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD.
Diabetes Care. 2022 Jul 7;45(7):1584-1591. doi: 10.2337/dc21-1977.
3
Use of nephrotoxic medications in adults with chronic kidney disease in Swedish and US routine care.
Clin Kidney J. 2021 Oct 29;15(3):442-451. doi: 10.1093/ckj/sfab210. eCollection 2022 Mar.
4
Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?
Curr Atheroscler Rep. 2020 Jul 15;22(8):43. doi: 10.1007/s11883-020-00860-w.
5
Management of Presumed Acute Kidney Injury during Hypertensive Therapy: Stay Calm and Carry on?
Am J Nephrol. 2020;51(2):108-115. doi: 10.1159/000505447. Epub 2020 Jan 15.
Zotero 插件